LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) has been recognized in an article in the February 2008 issue of Nature Biotechnology Magazine for its progressive development of a pharmacoeconomic strategy for the commercialization of its drug candidate CVBT-141H. The drug, which is moving into a US FDA approved Phase II clinical trial, treats severe coronary heart disease (CHD) and contains the active pharmaceutical ingredient (API) human fibroblast growth factor-1 (FGF-1).
